Johnson & Johnson‘s (NYSE:JNJ) Vision business said today that it closed its acquisition of ophthalmological medical device maker TearScience for an undisclosed amount.
Resarch Triangle Park, N.C.-based TearScience produces devices focused on treating meibomian gland dysfunction, a leading underlying cause of dry eye disease, Johnson & Johnson said. The company won FDA clearance for its office-based treatment of meibomian glands and treating MGD, with its devices available in the US and global markets.
“Dry eye is too often the culprit of why patients drop out of contact lenses or why they may have a less than optimal outcome from their cataract surgery,” J&J Vision chairwoman Ashley McEvoy said in a press release.. “The medical device technologies from TearScience will allow us to address the main underlying cause of Dry Eye, giving us a mechanical solution to a mechanical problem.”
Johnson & Johnson said the acquisition was made via its recently acquired Abbott Medical Optics division.
In July, J&J said its medical device division is rolling its Pulsar Vascular and Neuravi acquisitions, as well as its existing Codman Neuro neurological portfolio, into a new neurovascular business dubbed Cerenovus.
